Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Wedbush raised their Q1 2025 EPS estimates for Fate Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.42) per share for the quarter, up from their prior forecast of ($0.49). Wedbush has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($1.30) EPS and FY2028 earnings at ($1.84) EPS.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $1.57 million.

Several other research analysts have also commented on the stock. StockNews.com upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Wells Fargo & Company lowered their price objective on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday. Stifel Nicolaus reduced their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday. Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, November 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a report on Thursday. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.50.

Fate Therapeutics Stock Performance

FATE stock opened at $1.01 on Monday. Fate Therapeutics has a one year low of $0.88 and a one year high of $8.74. The firm has a market cap of $115.74 million, a price-to-earnings ratio of -0.61 and a beta of 2.26. The firm has a 50-day simple moving average of $1.36 and a two-hundred day simple moving average of $2.35.

Insider Activity at Fate Therapeutics

In other Fate Therapeutics news, Director Redmile Group, Llc bought 397,964 shares of Fate Therapeutics stock in a transaction that occurred on Friday, December 20th. The stock was purchased at an average price of $1.68 per share, with a total value of $668,579.52. Following the completion of the acquisition, the director now directly owns 12,884,277 shares in the company, valued at approximately $21,645,585.36. This trade represents a 3.19 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Fate Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC lifted its holdings in shares of Fate Therapeutics by 27.5% in the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 8,497 shares during the period. SG Americas Securities LLC lifted its holdings in Fate Therapeutics by 30.6% in the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 10,511 shares during the period. Geode Capital Management LLC boosted its position in Fate Therapeutics by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company’s stock worth $7,905,000 after purchasing an additional 10,863 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Fate Therapeutics by 6.6% during the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company’s stock worth $326,000 after purchasing an additional 12,295 shares during the period. Finally, Franklin Resources Inc. increased its holdings in shares of Fate Therapeutics by 9.6% during the 4th quarter. Franklin Resources Inc. now owns 165,353 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 14,532 shares in the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.